Under the terms of the agreement, Biopas will have exclusive rights to distribute, market, and seek reimbursement for Sialanar® within its paediatric indication in Argentina, Chile, Ecuador, Peru, Panama, Costa Rica, Colombia and Mexico. It is estimated that approximately 19,000 children with neurodisabilities suffer today from sialorrhoea in this Latin American region.
Continue reading